COMMUNIQUÉS West-GlobeNewswire

Bloom Healthcare Brings Its Proven In-Home Care Model to Dallas-Fort Worth Seniors
01/10/2026
Home-based geriatric care model brings personalized primary care to seniors across the region DENVER, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Bloom Healthcare , a passionate team of medical providers specializing in in-home [...]
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
01/10/2026
In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had [...]
FDA Grants Fast Track Designation for TRE-515 in Combination with KRAS G12C Inhibitors for the Treatment of Non-Small Cell Lung Cancer
01/10/2026
LOS ANGELES, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that [...]
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
01/10/2026
LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy Results presented in a late-breaking plenary session at IGCS [...]
NMDP Gala Highlights Financial Challenges Facing Patients in Need of Blood Stem Cell Transplants
01/10/2026
Patient financial assistance requests are up 34% as NMDP and its supporters work to help more families overcome barriers to treatment MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- With demand for financial assistance [...]
IBA SA – NOTIFICATION TRANSPARENCE
01/10/2026
(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 1 octobre 2026, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le [...]
IBA – TRANSPARENCY NOTIFICATION
01/10/2026
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, October 1, 2026 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading [...]
Life Biosciences to Present First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies at Eyecelerator 2026
01/10/2026
BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, today announced that the company will present new [...]
SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
01/10/2026
SpyGlass Pharma acquires 100% of the outstanding shares of AVS, a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), the existing manufacturer of SpyGlass Pharma’s intraocular lens (IOL) Secures scalable commercial [...]
ViCentra Presents Large-Scale Real-World Evidence Demonstrating Kaleido Insulin Patch Pump System Delivers Stable Glucose Control with Very Low Hypoglycemia
01/10/2026
Analysis of 3,918 adults across Germany, the Netherlands and France, with no eligibility criteria beyond active system use, covering 323,814 person-days of real-world experience Users achieved median time in range of 72 [...]
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
01/10/2026
Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis ( NCT06207370 ) to be disclosed on October 6, 2026. Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring [...]
BrightSpring Health Services, Inc. to Announce Third Quarter 2026 Financial Results on October 30, 2026
01/10/2026
LOUISVILLE, Ky., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its third quarter 2026 financial results on [...]
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
01/10/2026
PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, [...]
Medicana Highlights Robotic Prostate Surgery as 2026 Review Reports Recovery Benefits
01/10/2026
ISTANBUL, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Medicana Health Group is highlighting the role of robot-assisted surgery in prostate cancer treatment as a 2026 research review reports lower blood loss and shorter hospital [...]
New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)
01/10/2026
New codes streamline hospital billing, enable tracking of clinical outcomes, and expand access to QUELIMMUNE ® (SCD-PED) therapy Universal codes establish a framework to enable billing for future potential SCD [...]
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
01/10/2026
Patent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism Expands intellectual property portfolio supporting Akari’s novel payload and [...]
ViroMissile Completes First Dose Cohort of Phase I Trial of Intravenously-Dosed IDOV-2; Safety Review Committee Clears Advancement to Next Cohort
01/10/2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- ViroMissile , Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the completion of the first dose [...]
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
01/10/2026
Presentations will feature encore Phase 1 data highlighting the mechanism of action, redosing potential, and early C-peptide response associated with SAB-142, a fully human multi-specific ATG for Stage 3 type 1 diabetes [...]
Spectral AI Announces First Site Initiation Visit for DeepView System™ Clinical Study Supporting Label Expansion Strategy to Burns of the Head, Hands, and Feet
01/10/2026
DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]

Pages